www.ijirses.com ISSN: 2583-1658 | Volume: 2 Issue: 6 | 2022

Hydroxychloroquine or Chloroquine as accessible weapon to fight against COVID-19 pandemic

Shobhana Ramteke[a], Bharat Lal Sahu[b*]

[a]*Scientist C, Integrated Regional Office, Ministry of Environment, Forest & Climate Change, New Raipur, CG, India*

[b]*Assistant Professor, Deaprtment of Chemistry, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, CG, India*

Abstract: *No medications are at present affirmed for Coronavirus Disease-2019 (COVID-19), albeit some have been attempted. Taking into account late investigations and conversation on chloroquine (CQ) and hydroxychloroquine (HCQ), we intended to survey existing writing and important sites concerning these medications and COVID-19, antagonistic impacts identified with drugs, and related rules.The exact instrumental activities of CQ and HCQ against SARS-CoV-2 isn't seen, however, is likely multifactorial: Inhibition of SARS-CoV-2 viral passage by CQ utilizing impedance with the connection of the ganglioside-restricting space at the tip of the N-terminal area of the SARS-CoV-2 spike with the ACE-2 receptor and hindrance of pH-subordinate viral molecule endocytosis through the rise of endosomal pH by the powerless base CQ.In this review regarding viruses, for reasons presumably incompletely indistinguishable including alkalinization by CQ of the phagolysosome, a few investigations have demonstrated the adequacy of this atom, including against coronaviruses among which is the SARS-related coronavirus.CQ and HCQ have comparative properties and movement, yet the generally lower harmfulness profile with HCQ has driven most specialists to suggest HCQ over CQ while considering treatment of SARS-CoV-2 with one of these operators.*

Keywords: *COVID-19, chloroquine, hydroxychloroquine*

1. Introduction

The episode of COVID-19 brought about by the extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2/2019-nCoV) represents a genuine danger to worldwide general wellbeing and nearby economies. According to information accessible on different sites for COVID-19 diseases around the world, the cases are expanding exponentially. Such immense quantities of tainted and dead individuals require a critical interest of compelling, accessible, and reasonable medications to control and reduce the plague. The World Health Organization (WHO) proclaimed the Coronavirus disease (COVID-19) a pandemic on March 11, 2020. Until now, there is an earnest requirement for compelling medications against SARS-CoV-2. CQ and HCQ have been appeared to repress SARS-CoV-2 in vitro, and HCQ appears to be more successful than CQ **[1,2].** CQ with the formula (N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has some time to be utilized and to treat intestinal sickness and amebiasis. Be that as it may, Plasmodium falciparum created boundless protection from it. In the previous years, because of inconsistent usage of CQ in clinical practice, its creation and market flexibly were extraordinarily decreased, in any event in China. The pandemic COVID-19 has pushed the worldwide social insurance framework to an emergency and added up to a tremendous monetary weight. Various medications for prophylaxis against COVID-19 including CQ and HCQ have been attempted. CQ is a prescription with a long history as an enemy of an intestinal sickness operator. Late intrigue was produced for the potential utilization of CQ for people with COVID-19 dependent on in vitro information that showed wide antiviral properties, including action against SARS-CoV-2. This potential has not been borne out in creature preliminaries and current clinical information is missing in regards to the treatment of COVID-19 disease with CQ. CQ and HCQ share a comparative instrument of activity; however accessible in vitro information shows that HCQ has a fundamentally more prominent intensity against SARS-CoV-2 than CQ, in light of its essentially lower powerful focus (EC50) esteem contrasted and HCQ [**3-4**].

Over a billion Indians as of now remain at the incline of a monstrous increment in instances of COVID-19. The Indian Council of Medical Research, (ICMR) under the Ministry of Health and Family Welfare, has suggested the chemoprophylaxis with HCQ (400 mg twice on day 1, at that point 400 mg once per week from that point) for asymptomatic human services laborers treating patients with suspected or affirmed COVID-19, and for asymptomatic family unit contacts of affirmed cases **[5].** The archive expresses "its utilization in prophylaxis is gotten from accessible proof of advantage as treatment and bolstered by preclinical information". Albeit some in-vitro proof backings the antiviral action of HCQ and its antecedent CQ, there is no companion looked into a distribution that assesses either medicate for presentation prophylaxis of SARS-

CoV-2 disease. In any event, for treatment of analyzed cases, just a single little examination announced quicker nasopharyngeal viral freedom, without any information for clinical improvement [**6**].This proof, or the deficiency in that department, scarcely legitimizes state-supported, across the board utilization of HCQ for prophylaxis. We are profoundly worried that in this condition of worldwide frenzy, an underwriting by the most elevated logical assemblage of India (and by the President of the USA) will make an excessively hopeful view of the adequacy of HCQ among people in general. Markets in the USA are now announcing a short flexibly of both HCQ and CQ. In these disorderly occasions, no social insurance framework can screen such countless solid contacts for associative QTc drawing out medications, long QT conditions, or glucose-6-phosphate dehydrogenase lack. The medication is untested, the advantages obscure, and the dangers not insignificant, particularly at this size of use **[7]**. Besides, the security of these immunomodulators in individuals in danger of a serious viral disease has never been assessed. A progressing pandemic legitimizes breathing space in age and translation of proof in light of a legitimate concern for general wellbeing. Be that as it may, all logical thinking can't be relinquished referring to edgy occasions. A sweeping proposal for chemoprophylaxis without valid proof may be combative no doubt. On the off chance that HCQ is to be utilized, an unmistakable educated decision should be offered to each contact, clarifying the shortage of proof for its adequacy and its latent capacity dangers. Moreover, all result occasions ought to be recorded. On the off chance that this isn't done, the hazard advantage appraisal would be slanted, antagonistic occasions acknowledged as inadvertent blow-back, and a medication acknowledged temporarily in a period of emergency could get ordinary as the standard of care for quite a while to come **[8].**

1.1. Treatment for COVID-19

Due to the COVID-19 outbreak still there is no antiviral treatment or no vaccine to cure from the COVID-19 and to identify the drug treatment as soon as possible. According to WHO report he has announced that SARS-CoV-2 vaccine will be available in 17-18 months of duration and as it required various funding to be maintained even if the level falls from SARS-CoV-2 **[9,10]**. The treatment for SARS-CoV-2 that includes general strategies to be follow that includes immunomodulating therapy, bronchoalveolar lavage, respiratory support, antiviral therapy, blood purification. Novel coronavirus infection is a new communicable disease with an emergent outbreak that affects all populations from India and worldwide. [**9**]

2. Mechanism of action of CQ and HCQ

CQ and HCQ are 4-aminoquinoline compounds, derivatives of quinine, and have been utilized as antimalarial drugs since the 1940s. HCQ is an analogue of CQ in which one of the N-ethyl substituents of CQ is β-hydroxylated respectively. HCQ and CQ have comparable pharmacokinetic properties, with high oral bioavailability and tissue penetrance, fractional hepatic digestion, and high volumes of circulation as they diffuse into fat tissue [**9].** The two medications have been utilized broadly and for a long time for treatment and prophylaxis of malaria and treatment of rheumatological conditions, for example, fundamental lupus erythematosus and rheumatoid arthritis [**11,12**]. The instrument of activity in the treatment and anticipation of malaria is thought to result from the hindrance of the biocrystallization of hemozoin, causing cytotoxic amassing of heme. For rheumatological conditions, the component of activity isn't completely depicted, yet seems to emerge from different impacts. As feeble bases, both CQ and HCQ gather in the acidic condition inside lysosomes, and in this way meddle with lysosomal action and autophagy, which thusly may hinder major histocompatibility complex (MHC) class II articulation and antigen introduction, repressing invulnerable activation [**11**]. CQ and HCQ additionally meddle with Toll-like receptor (TLR) flagging, again employing changes to neighborhood pH yet also through direct authoritative to nucleic acids. TLR signal pathways animate cytokine creation, and CQ and HCQ have been exhibited to hinder the creation of different cytokines including interleukin IL-1, IL-6, tumor necrosis factor (TNF), and interferon-gamma (IFNγ) by mononuclear cells [**13**]. The exact instrument of activity of CQ and HCQ against SARS-CoV-2 isn't completely seen, however, is likely multifactorial: Inhibition of SARS-CoV-2 viral section by CQ through the obstruction with the connection of the ganglioside-restricting area at the tip of the N-terminal space of the SARS-CoV-2 spike with the ACE2 receptor and hindrance of pH-subordinate viral molecule endocytosis utilizing the height of endosomal pH by the frail base CQ. Hindrance of endocytosis by decreasing the outflow of phosphatidylinositol binding clathrin assembly protein (PICALM), a bottomless protein in clathrin pits that helps shape the layer invagination during the endocytosis procedure. Aggregation and pH height in layer organelles that ordinarily have a low pH, in this manner constricting viral protein action that commonly relies upon low pH for ideal action, just as hindering fundamental post-translational polyprotein adjustments. Hindrance of viral get together in the

endoplasmic reticulum-Golgi intermediate compartment (ERGIC)-like structures through hazy systems and CQ effectively affects cell/organelle capacities, for example, Immunomodulatory impacts that can be utilized to treat rheumatological conditions, Alkalinezesvacuolar (and lysosomal) pH as CQ is soluble and restrains protozoal food vacuole working and lysosomal combination and capacity and CQ is a zinc ionosphere which permits deluge of zinc into cells and lysosomes and may have hostile to malignant growth impacts too (**Figure. 1).**



Figure -1: Chloroquine Antiviral Properties against SARS-CoV-2

HCQ has immunomodulatory properties and an appealing antagonistic impact profile [**2**]. It could add to the concealment of the cytokine discharge disorder liable for the movement of COVID-19 to serious clinical structures through a few components including, a decrease of T cell initiation and separation, diminished creation of cytokines by T cells and B cells (for example IL-1, IL-6, and TNF), and weakening of ace provocative flagging pathways actuation. Strangely, HCQ and CQ repress receptor authoritative and layer combination, two basic advances required for cell section by coronaviruses. Be that as it may, HCQ offers points of interest contrasted and CQ: better clinical wellbeing profile, conceivable higher day by day portion, and less pharmacological interactions [**1,2**] (**Figure. 2**).



Figure -2: Hydroxychloroquine antiviral Properties against SARS-CoV-2

2.1Convalescent plasma therapy

Plasma therapy could be an effective way to cure the course of disease for severely SARS-CoV-2 infected patients when there are no sufficient vaccines or specific drugs, present at the moment. A previous cohort study by Hung et al. has reported that for patients with pandemic H1N1 influenza virus infection in 2009, the relative risk of death was significantly lower in patients treated with convalescent plasma. With the serum of the patient who recover from the COVID-19 infection can be used from the immunology and prevent reinfection in the body. Another is the antibodies that can limits the viral reproduction in the acute phase and cure the viral disease. Plasma therapy is to be given in the first week of the viral infections [**14**]. Therefore, the plasma of patients who have recovered from COVID-19 could be collected to prepare plasma globulin specific to SARS-CoV-2. However, the safety of plasma globulin products specific to SARS-CoV-2 deserves consideration in further **Figure 3**.



Figure -3: Convalescent plasma therapy for treating coronavirus

2.2Antiviral therapy

Till the review of the article the antiviral drug i.e Remdesivir $C_{27}H_{35}N_6O_8P$ with 602.585 g·mol^{-1} with a nucleotide analog is been found to be useful in patient from America with COVID-19 positive and it is been confirmed. For the treatment of Ebola and Marlburg viruses it used and it is a novel antiviral that was developed by Gilead recently. Meanwhile for the previous viruses such as MERS and SARS were also demonstrated possible inhibition of other single stranded RNA viruses. Braced these, Gilead has provided the compound to China to conduct a pair of trials on SARS-CoV-2-infected individuals, and therefore the results are highly anticipated and recommended. In addition, some more antiviral drugs such as Baricitinb, Interferon-α, Lopinavir/ritonavir, and Ribavirin etc are alsosuggested as potential therapies for patients with acute respiratory symptoms [**15**]. In the combined therapy with lopinavir/ritonavir drugs vomiting, nausea, diarrhea, liver damage, and other adverse reactions can occur. The interaction of

those treatments with other drugs utilized in the patients should be monitored carefully **Figure 4.**



Figure 4: Remdesivir Antiviral Properties against SARS-CoV-2

2.3 Host-Targeted Strategies

A few safe modulator medications, for example, chloroquine, nitazoxanide, and ribavirin in blend of PEGylated interferon alfa-2a and - 2b have demonstrated inhibitory activity against SARS-CoV-2 contamination [**16**]. An ongoing report has appeared that chloroquine is progressively powerful to forestall SARS-CoV-2 contamination in cell culture model contrasted with other tried medications and furthermore in an open-name preliminary for the treatment of SARS-CoV-2 contamination in patients **Figure 5.**



Figure 5: Various host targeted Strategies to fight against SARS-CoV-2

3. Discussion

In this review regarding viruses, for reasons presumably somewhat indistinguishable including alkalinization by CQ of the phagolysosome, a few investigations have indicated the viability of this atom, including against coronaviruses among which is the SARS-related coronavirus [**17-19**]. We recently stressed enthusiasm for CQ for the treatment of viral contaminations in this journal10, foreseeing its utilization in viral diseases lacking medications. Following the revelation in China of the in vitro movement of CQ against SARS-CoV-2, found during society tests on Vero E6 cells with 50% and 90% effective concentrations (EC_{50} and EC_{90} values) of 1.13 µM and 6.90 µM, separately (antiviral action being seen when the expansion of this medication was completed previously or after viral contamination of the cells), we anticipated with incredible intrigue the clinical data [**20-21**]. The ensuing in vivo information was conveyed following the primary aftereffects of clinical preliminaries by Chinese groups and excited extraordinary energy among us. They demonstrated that CQ could decrease the length of emergency clinics remain and improve the advancement of COVID-19 pneumonia16, prompting suggests the organization of 500 mg of CQ two times every day in patients with gentle, moderate, and extreme types of COVID-19 pneumonia. At such a dose, a restorative centralization of CQ may be reached. With our experience on 2000 doses of HCQ during the previous 5 years in patients with long haul treatment (>1 year), we realize that with a dose of 600 mg/day we arrive at centralization of 1 µg/mL. The ideal measurement for SARS-CoV-2 is an issue that should be surveyed in the coming days. For ideal treatment, it might be important to direct a stacking portion followed by an upkeep dose [**22-29**].

4. Adverse Effect

CQ and HCQ have comparable properties and action, however, the generally lower poisonousness profile with HCQ has driven most specialists to suggest HCQ over CQ while considering treatment of SARS-CoV-2 with one of these operators. In the case of utilizing CQ, most unfavourable occasions are related to delayed use. Of note, retinal issues are accounted for just with long haul use. The accompanying features the most well-known and significant unfriendly impacts related to transient utilization of CQ are Hypoglycemia because of diminished insulin leeway, Mild queasiness, and the runs and QT prolongation [**30-32**].

5. Conclusion

The COVID-19 pandemic has pushed the India and worldwide human services framework to an emergency and hence, added up to a gigantic financial and cultural weight. The avoidance of the virus transmission of the malady in the populace, especially among the high hazard infected people, is the dire need of great importance. In the COVID-19 pandemic various medications for prophylaxis has been including such as CQ or HCQ, Remdesivir and plasma therapy have been attempted respectively. Even though the pre-clinical outcomes are to be promising, and to date there is a deficiency of acceptable quality proof to help the clinical viability of CQ or HCQ and Remdesivir in forestalling COVID-19 situation. Different medications for prophylaxis against COVID-19 including HCQ and

CQ have been investigated. Even though pre-clinical outcomes are promising, till date there is a lack of acceptable quality proof to help the clinical adequacy of CQ and HCQ in preventing COVID-19 pandemic situation the prophylactic utilization of CQ or Remdesivir against COVID-19 should be additionally explored as more information pour should be in.

Conflict of interests: The authors declare no conflict of interest.

References

[1] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Yufeng L, Zhihong H , Wu Z and Manli W "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro". Nature Cell Discovery, Vol 6, pp 16, 2020.

[2] Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Xu L, Li Z, Erdan D, Chunli S, Siyan Z, Roujian L, Haiyan L, Wenjie T, Dongyang L. "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infection Disease, Vol 28, Issue 71(15), pp732-739. 2020. https://doi.org/10.1093/cid/ciaa237."

[3] Weniger, H. "Review of side effects and toxicity of chloroquine". Bulltein World Health, Vol 79, pp 906, 1979. https://apps.who.int/iris/handle/10665/65773.

[4] McChesney, EW. "Animal toxicity and pharmacokinetics of hydroxychloroquine Sulfate". American Journal of Medicine, Vol 75, pp11–18, 1983. https://doi.org/10.1016/0002-9343(83)91265-2.

[5] Our World in Data. "Total and daily confirmed COVID-19 cases, India". 2020. Available from: https://ourworldindata.org/grapher/total-and-dailycases-covid-19?country=IND (accessed April 8, 2020).

[6] National Taskforce for COVID-19. "Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection". 2020. Availablefrom:https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infecti on.pdf (accessed March 23, 2020).

[7] Mandal S, Bhatnagar T, Arinaminpathy N, Agrawal A, Chowdhery A, Murhekae M, Raman RG, Swarup S. "Prudent public health intervention strategies to control the coronavirus disease 2019 transmission in India: a mathematical model-based approach". The Indian Journal of Medicine Research, Vol 151, pp190–199, 2020. https://doi.org/10.4103/ijmr.ijmr_504_20.

[8] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Barbara D, Johan C, Valérie G, Vera Esteves V, Hervé Tissot D, Stéphane H, Philippe C, Eric C, Bernard La S, Jean-Marc R, Philippe B, Didier R. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial". International Journal of Antimicrobial Agents, Vol 20, pp105949, 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949.

[9] Wang, X., Peng, Z., "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus– Infected Pneumonia in Wuhan, China". JAMA, 2020

[10] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Li Zhang, Guohui F, Jiuyang X, Xiaoying G, Zhenshun C, Ting Y, Jiaan X, Yuan W, Wenjuan W, Xuelei X, Wen Y, Hui L, Min L, Yan X, Hong G, Li G, Jungang X, Guangfa W, Rongmeng J, Zhancheng G, Qi J, Jianwei W, Bin C. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan", China. The Lancet, Vol 395, pp497-506, 2020.

[11] Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. "Hydroxychloroquine: from malaria to autoimmunity". Clinical Rev Allergy & Immunology, Vol 42, Issue (2), pp145–53, 2012.https://doi.org/10.1007/s12016-010-8243-x.

[12] Schrezenmeier E, Dörner T. (2020) "Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology". Nature Reviews Rheumatology, Vol 16, Issue (3), pp155–166, 2020.https://www.nature.com/articles/s41584-020-0372-x#citeas

[13] Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, et al. "Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review". Z Rheumatol , 2020. https://doi.org/10.1007/s00393-020-00751-0

[14] The FDA previously provided guidance on emergency use of COVID-19 convalescent plasma: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds

[15] Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. "Coronaviruses - drug discovery and therapeutic options". Nat Rev Drug Discov, Vol 15, pp327-47, 2016.

[16] Li G, De Clercq E "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nat Rev Drug Discovery.2020. https://doi.org/10.1038/d41573-020-00016-0

[17] Borne BE, Dijkmans BA, Rooij HH, Cessie S, Verweij CL. "Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells". Journal of Rheumatology, Vol 24, Issue (1),pp55–60, 1997.

[18] Rolain, JM, Colson, P, Raoult D. "Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century". International Journal of Antimicrobial Agents, Vol 30,pp297–308, 2007. https://doi.org/10.1016/j.ijantimicag.2007.05.015

[19] Keyaerts, E, Vijgen, L, Maes, P, Neyts, J, Van Ranst M. "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine".Biochem Biophysics Research Communication, Vol 323, pp 264–268, 2004. https://doi.org/10.1016/j.bbrc.2004.08.085.

[20] Savarino, A, Trani, LD, Donatelli, I, Cauda R, Cassone A. (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6:67-69, https://doi.org/10.1016/s1473-3099(06)70361-9.

[21] Wang, M, Cao, R, Zhang, L, Yang, X, Liu, J, Xu, M. *et al.*"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",Cell Research, Vol 30, pp269–271, 2020. https://www.nature.com/articles/s41422-020-0282-0#citeas

[22] P. Colson, J.M. Rolain, D. Raoult "Chloroquine for the 2019 novel coronavirus SARS-CoV-2". International Journal of Antimicrobial Agents, Vol 55, pp105923, 2020. https://doi.org/10.1016/j.ijantimicag.2020.105923

[23] Lagier JC, Fenollar F, Lepidi H, Giorgi R, Million M , Raoult D. "Treatment of classic Whipple's disease: from in vitro results to clinical outcome". Journal of Antimicrobial Chemother, Vol 69, pp219–227, 2014. https://doi.org/10.1093/jac/dkt310

[24] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, T.G. Ksiazek TG, *et al.* "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread". Virology Journal, Vol 2, pp 69, 2005. https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69#citeas

[25] Barnard DL, Day, CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, *et al.*"Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice".Antivir Chem Chemother, Vol 17, pp275–284, 2006. https://doi.org/10.1177/095632020601700505.

[26] Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D. *et al.* "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities". Journal of Medicine Chemistry, Vol 49, pp 2845–2849,2006, https://doi.org/10.1021/jm0601856

[27] Kono M, Tatsumi K, Imai, AM, Saito K, Kuriyama T, ShirasawaH."Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK". Antiviral Research, Vol 77, pp150–152,2008, https://doi.org/10.1016/j.antiviral.2007.10.011

[28] Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M.. "Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice".Antimicrob Agents Chemother, Vol 53,pp 3416–3421,2009, DOI: 10.1128/AAC.01509-08.

[29] De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM,*l.* "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture".Antimicrob Agents Chemother, Vol 58, pp 4875–4884, 2014, https://doi.org/10.1128/aac.03011-14

[30] U.S. Food and Drug Administration (FDA). "Fact sheet for health care providers emergency use authorization (EAU) of chloroquine phosphate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients". Available from: https://www.federalregister.gov/documents/2020/03/06/2020-04630/policy-for-diagnostics-testing-in-laboratories-certified-to-perform-high-complexity-testing-under

[31] Leden I. "Digoxin- hydroxychloroquine interaction? Acta Med Scand, Vol 211, pp 411–2, 1982https://doi.org/10.1111/j.0954-6820.1982.tb01971.x

[32] Lewis J, Gregorian T, Portillo I, Goad J. "Drug interactions with antimalarial medications in older travelers: a clinical guide". Journal of Travel Medicine, Vol 27, Issue (1), pp089, 2020,https://doi.org/10.1093/jtm/taz089

Authors' Biographies

Dr. Shobhana Ramteke is a Scientist 'C' at Integrated Regional Office, Ministry of Environment, Forest & Climate Change, New Raipur Chhattisgarh. She has published more than 35 papers and 06 book chapters in well reputed journals as first or coauthor.

Dr. Bharat Lal Sahu is an Assistant Professor at Department of Chemistry, Guru Ghasidas Vishwavidyalaya (A Central University). He has published more than 40 papers and 10 book chapters in well reputed journals as first or coauthor.